Myanmar PharmaBurma Pharma
We are one of the leading manufacturers of generics in Myanmar and have a significant market value among physicians. We offer a wide range of products in the areas of anti-infectives, neuropsychiatry, cardio, gastro-intestinal, diabetology, pulmonary diseases, orthopedics, gynecology, ocology, eye phthalmology, utilrology, pain treatment, OTC, Erectile Dystrophy and antiretroviral treatment (ARV). We are a leader in anti-infectives, heart circulation, neuroscience, mental health, OTC and intestines.
In Myanmar, our activities are backed by a strong dedication to excellence through R&D and production worldwide. We have 41 production sites on 5 Continent to support our worldwide footprint.
Myanmar's first private pharmaceutical factory is opened in the municipality of Dagon Seikkan.
Myanmar's first private pharmaceuticals plant opened its gates in Dagon Seikkan Township, Yangon, in the third weeks of July. Pacific Medical Industries Limited (PMI) is situated in Industrial Zone 1 and consists of a two-story office complex, a QA area and a vast production area of 16,630 sqm.
To reduce the country's dependence on imports of pharmaceuticals, Zaw Moe Khaing, the company's chief executive officer, established a state-of-the-art plant that complies with global norms while at the same time supplying the Myanmar community with cheap medicines. "Ninety per cent of the drugs used in Myanmar are exported. Myanmar is also the only state in the ASEAN area where there is no private production of pharmaceuticals," said U Zaw Moe Khaing, Chief Executive Officer of the Pacific AA Group.
In Myanmar, pharmaceutical production is highly dependent on India, Thailand, the Philippines, France, the USA and China. PMI's $20 million plant will address the country's medical problems by constructing the first plant in Myanmar to obtain U.S. Food & Drug Administration regulatory approvals for the manufacture of pharmaceuticals in supplement to its FDA approvals.
PMI is in strict compliance with WHO and EU GMP directives and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), an internationally operating treaty governing the manufacture of pharmaceuticals. Zaw Moe Khaing wants the consumer security and superior performance of his plant to surpass that of his inferior competitors in neighbouring Bangladesh and China.
PMI will begin with 50 different kinds of medicines, from basic dental prodcuts such as pills, capsule and powder to advanced drugs to treat conditions such as hypertension, diabetic and cardiac diseases," said Dr. Saw Nay Nwal, Executive Director of Pacific AA Group. "We will provide affordable health care by developing local manufactured goods that comply with global health and welfare standards," said Dr. Saw Nay Nwal.
Myanmar's present domestic pharmaceuticals manufacturing is restricted to state-owned companies run by the Ministry of Industry. Since the end of the 1950', two plants producing about 200 kinds of medicines have been operating under the Myanmarceutical Industries name.